Follow
Thomas Rutkoski
Thomas Rutkoski
Associate Scientific Director, Janssen Research and Development
Verified email at its.jnj.com
Title
Cited by
Cited by
Year
Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers
SB Peng, JR Henry, MD Kaufman, WP Lu, BD Smith, S Vogeti, ...
Cancer cell 28 (3), 384-398, 2015
2792015
Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants
BD Smith, MD Kaufman, WP Lu, A Gupta, CB Leary, SC Wise, TJ Rutkoski, ...
Cancer cell 35 (5), 738-751. e9, 2019
2442019
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036
WW Chan, SC Wise, MD Kaufman, YM Ahn, CL Ensinger, T Haack, ...
Cancer cell 19 (4), 556-568, 2011
2282011
Tuning the pKa of Fluorescein to Optimize Binding Assays
LD Lavis, TJ Rutkoski, RT Raines
Analytical chemistry 79 (17), 6775-6782, 2007
2052007
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas, RP Taylor, MR Cunningham, TJ Rutkoski, J Vennarini, H Jang, ...
Journal of Pharmacology and Experimental Therapeutics 313 (2), 578-585, 2005
1782005
Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity
TJ Rutkoski, RT Raines
Current pharmaceutical biotechnology 9 (3), 185-199, 2008
1482008
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal …
JR Henry, MD Kaufman, SB Peng, YM Ahn, TM Caldwell, L Vogeti, ...
Journal of medicinal chemistry 58 (10), 4165-4179, 2015
932015
Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A
TJ Rutkoski, EL Kurten, JC Mitchell, RT Raines
Journal of molecular biology 354 (1), 41-54, 2005
922005
Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2
BD Smith, MD Kaufman, CB Leary, BA Turner, SC Wise, YM Ahn, ...
Molecular cancer therapeutics 14 (9), 2023-2034, 2015
742015
Structure, dynamics, and specificity of endoglucanase D from Clostridium cellulovorans
CM Bianchetti, P Brumm, RW Smith, K Dyer, GL Hura, TJ Rutkoski, ...
Journal of molecular biology 425 (22), 4267-4285, 2013
522013
Increasing the potency of a cytotoxin with an arginine graft
SM Fuchs, TJ Rutkoski, VM Kung, RT Groeschl, RT Raines
Protein Engineering, Design & Selection 20 (10), 505-509, 2007
462007
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering
TJ Rutkoski, JA Kink, LE Strong, CI Schilling, RT Raines
Bioconjugate chemistry 21 (9), 1691-1702, 2010
292010
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
J Cortes, M Talpaz, HP Smith, DS Snyder, J Khoury, KN Bhalla, ...
Haematologica 102 (3), 519, 2017
282017
Cytotoxic ribonuclease variants
RT Raines, JC Mitchell, TJ Rutkoski
US Patent 7,416,875, 2008
282008
DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models
BD Smith, MM Hood, SC Wise, MD Kaufman, WP Lu, T Rutkoski, DL Flynn, ...
Cancer Research 75 (15_Supplement), 2690-2690, 2015
182015
Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity
TJ Rutkoski, JA Kink, LE Strong, RT Raines
Cancer Biology & Therapy 12 (3), 208-214, 2011
182011
Human ribonuclease with a pendant poly (ethylene glycol) inhibits tumor growth in mice
TJ Rutkoski, JA Kink, LE Strong, RT Raines
Translational Oncology 6 (4), 392-397, 2013
142013
Serum albumin-binding fibronectin type III domains
M Diem, S Jacobs, K O'neil, T Rutkoski
US Patent 10,925,932, 2021
102021
Compositions and methods for ribonuclease-based therapeutics
RT Raines, TJ Rutkoski, JA Kink, LE Strong
US Patent 8,697,062, 2014
92014
Effectiveness and limitations of local structural entropy optimization in the thermal stabilization of mesophilic and thermophilic adenylate kinases
S Moon, RM Bannen, TJ Rutkoski, GN Phillips Jr, E Bae
Proteins: Structure, Function, and Bioinformatics 82 (10), 2631-2642, 2014
82014
The system can't perform the operation now. Try again later.
Articles 1–20